Sharma P L, Sapru R P
Int J Clin Pharmacol Biopharm. 1978 Feb;16(2):83-5.
A study on the comparative potency of intravenously administered penbutolol, a new non-selective beta adrenoceptor antagonist, on the resting and post-exercise heart rate and rate-pressure product was carried out in 5 normal human subjects. The effects produced by 0.1, 0.2 and 0.3 mg of penbutolol and of 0.025 mg/kg (mean dose 1.28 mg) of propranolol was recorded. The dose of penbutolol producing an effect equivalent to that of propranolol was calculating from the log dose-response curve of penbutolol. In these tests, penbutolol was 7.90 and 7.66 times more potent than propranolol on a weight to weight basis. Penbutolol was well tolerated and no side-effects were observed.
对5名正常人类受试者进行了一项研究,以比较静脉注射新型非选择性β肾上腺素能受体拮抗剂喷布洛尔对静息心率和运动后心率以及心率-血压乘积的效能。记录了0.1、0.2和0.3毫克喷布洛尔以及0.025毫克/千克(平均剂量1.28毫克)普萘洛尔产生的效果。根据喷布洛尔的对数剂量-反应曲线计算出产生与普萘洛尔等效效果的喷布洛尔剂量。在这些试验中,按重量计算,喷布洛尔的效能比普萘洛尔高7.90倍和7.66倍。喷布洛尔耐受性良好,未观察到副作用。